FluoGuide A/S

Stockholm Stock Exchange FLUO.ST

FluoGuide A/S Free Cash Flow Yield on January 14, 2025: -8.69%

FluoGuide A/S Free Cash Flow Yield is -8.69% on January 14, 2025, a -57.95% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

FluoGuide A/S 52-week high Free Cash Flow Yield is -5.50% on January 15, 2024, which is 36.69% above the current Free Cash Flow Yield.
FluoGuide A/S 52-week low Free Cash Flow Yield is -11.25% on November 13, 2024, which is -29.53% below the current Free Cash Flow Yield.
FluoGuide A/S average Free Cash Flow Yield for the last 52 weeks is -8.39%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: FLUO.ST

FluoGuide A/S

CEO	Mr. Morten Albrechtsen B.B.A., BBA, M.D.
IPO Date	June 17, 2019
Location	Denmark
Headquarters	Ole MaalOees Vej 3
Employees	7
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.

Key trends

Past 5 years